Clinical Trials Browser

Breast Neoplasms, Breast Neoplasms, Male

Prostatic Neoplasms

Prostate Adenocarcinoma

Neoplasm Metastasis, Prostatic Neoplasms

Prostate Adenocarcinoma

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Salivary Gland Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Prostatic Neoplasms

Prostatic Neoplasms

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Hormone Sensitive Prostate Cancer

Stage I Prostate Adenocarcinoma AJCC v7

Prostatic Neoplasms

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Salivary Gland Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Prostatic Neoplasms

HER2-positive Breast Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Castrate Sensitive Prostate Cancer

Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Clinical Trials

Adjuvant WIDER

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

VA STARPORT

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Roll-over Study to Allow Continued Access to Ribociclib

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

preEMBER

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

THUNDER

CARABELA

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

ARCH

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

PETREMAC

e3

CASPAR

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NePtune

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

BYLieve

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

STEEL

DIVINE

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

EVANGELINE

AMALEE

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

The COSMYC Trial (COmbined Suppression of MYC)

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

AMEERA-5

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

FASCINATE-N

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer